AMENDMENT UNDER 37 C.F.R. §1.111 U.S. Appln. No. 09/493,211

R¹, R², and R³ are each an amino acid and may be the same or different,

a is an integer from 0 to 15,

b is an integer from 0 to 15,

wherein the combination of a + b is not greater than 15,

c is an integer from 0 to 15,

each A is an amino acid independently selected from the group consisting of Lys, Arg and His,

each B is an amino acid independently selected from the group consisting of Phe, Trp and Tyr,

each C is an amino acid independently selected from the group consisting of Leu, Ile, Val and Ala,

X is either (A-B-C-A) or (A-C-B-A), m is an integer of from 2 to 8, and

n is an integer of from 1 to 3.

3. (Amended) The purified peptide according to claim 1, wherein a + b and c are each an integer of from 1 to 10.

4. (Twice amended) The purified peptide according to claim 1, wherein R¹_a is

selected from the group consisting of:

Glyp, wherein p is an integer of from 1 to 10; and

Alaq, wherein q is an integer of from 1 to 10.

8. (Thrice amended) A peptide comprising amino acids 1 to 19 of SEQ ID NO: 1.

9. (Thrice amended) A peptide comprising amino acids 1 to 19 of SEQ ID NO: 2.

Sub-F1



AMENDMENT UNDER 37 C.F.R. §1.111 U.S. Appln. No. 09/493,211

- 10. (Thrice amended) A peptide comprising amino acids 1 to 19 of SEQ ID NO: 3.
- 11. (Thrice amended) A peptide comprising amino acids 1 to 19 of SEQ ID NO: 4.
- 12. (Thrice amended) A peptide comprising amino acids 1 to 29 of SEQ ID NO: 5.

15. (Twice amended) A pharmaceutical composition comprising a peptide according to claim 1 as an active component and apharmaceutically acceptable carrier in a pharmaceutically acceptable dosage form.

Please add the following new claims:

- 48. The purified peptide according to claim 1, wherein R² is ACAA, wherein each A and C is as independently defined in claim 1.
- 49. The pharmaceutical composition according to claim 15, wherein said peptide is present in said composition in an amount effective to treat one or more of the conditions selected from the group consisting of a topical microbial infection, a topical parasitic infection, a systemic microbial infection, a systemic parasitic infection, a topical tumor, a systemic tumor, inflammation and bacterial septic shock.

The pharmaceutical composition according to claim 15, wherein said composition is in the form of a topical preparation, a parenteral preparation or an oral preparation.